Latest & greatest articles for hepatitis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for hepatitis

161. Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V

Ledipasvir/sofosbuvir (hepatitis C) ? Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Ledipasvir/Sofosbuvir (chronische Hepatitis C bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 November 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG (...) Reports – Commission No. A17-41 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-41 Version 1.0 Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) 13 November 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Ledipasvir/sofosbuvir (chronic hepatitis C in adolescents) – Benefit

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

162. Autoimmune hepatitis

Autoimmune hepatitis Autoimmune hepatitis - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Autoimmune hepatitis Last reviewed: February 2019 Last updated: March 2018 Summary More frequently affects women and has a variable course with different clinical manifestations, ranging from no symptoms to fulminant hepatic failure. Concurrent autoimmune diseases are often present. Aminotransferase levels are usually more (...) is indicated in patients with advanced liver disease who are refractory or intolerant to corticosteroid therapy. Definition Autoimmune hepatitis (AIH) is a chronic inflammatory disease of the liver of unknown aetiology. It is characterised by the presence of circulating auto-antibodies with a high serum globulin concentration, inflammatory changes on liver histology, and a favourable response to immunosuppressive treatment. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune

2018 BMJ Best Practice

163. Hepatitis B

Hepatitis B Hepatitis B - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatitis B Last reviewed: February 2019 Last updated: April 2018 Summary Most people are asymptomatic, although some will present with complications such as cirrhosis, hepatocellular carcinoma, or liver failure. People from endemic areas (Asia, Africa), or injection drug users and those with high-risk sexual behaviours, are at an increased risk (...) interferon-alfa. Definition Hepatitis B virus (HBV) is a DNA virus transmitted by percutaneous and permucosal routes. HBV infection is also a sexually transmitted disease. Infection may result in a self-limiting disease requiring no treatment, particularly in adult-acquired infection, but it may also result in a chronically infected state, particularly if it is acquired perinatally or in early childhood. History and exam presence of risk factors normal physical examination jaundice hepatomegaly ascites

2018 BMJ Best Practice

164. Hepatitis C

Hepatitis C Hepatitis C - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatitis C Last reviewed: February 2019 Last updated: June 2018 Summary Transmission is through percutaneous exposure to infected blood, most commonly through injection of illicit drugs or transfusion of contaminated blood products in developed countries, or via contaminated medical or dental equipment in resource-poor countries. Following acute (...) exposure to hepatitis C virus, about 55% to 85% of patients develop chronic hepatitis C. Most infections are asymptomatic; however, hepatic inflammation is often present and can lead to progressive hepatic fibrosis. The goal of treatment is to eradicate the virus, achieve a sustained virological response, and prevent disease progression. Oral direct-acting antiviral therapies are standard treatment; therapy is evolving at a rapid pace. Long-term complications of chronic infection include cirrhosis

2018 BMJ Best Practice

165. Hepatitis A

Hepatitis A Hepatitis A - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Hepatitis A Last reviewed: February 2019 Last updated: March 2018 Summary Transmission of Hepatits A usually precedes symptoms by 2 weeks when stool concentrations are highest. Patients are considered non-infectious 1 week after onset of jaundice. Symptomatic patients may present with abrupt-onset fever, abdominal pain, malaise, and jaundice. IgM (...) anti-hepatitis A virus serology is the test of choice for diagnosis. Common examination findings are hepatomegaly and clinical jaundice with marked elevation of serum transaminases (usually >1000 units/L). No specific therapy is available and treatment is supportive. Post-exposure prophylaxis may be with active or passive immunisation, depending on specific patient factors, and according to individual national guidelines. Definition Hepatitis A virus (HAV) is an RNA virus. It is not associated

2018 BMJ Best Practice

166. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma (Abstract)

Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma Hepatic resection and radiofrequency ablation (RFA) are treatment options for early-stage hepatocellular carcinoma (HCC). Whether tumour recurrence and long-term survival favour either treatment has not been established. This randomized trial aimed to test the hypothesis that RFA is superior to hepatic resection in terms of lower tumour recurrence rate and better long-term (...) survival.Patients with early-stage HCC (solitary tumour no larger than 5 cm; or no more than 3 tumours, each 3 cm or smaller) were randomized into hepatic resection and RFA groups. Demographic and clinical characteristics, and short- and long-term outcome measures were compared between groups. Primary and secondary outcome measures were overall tumour recurrence and survival respectively.Clinicopathological data were similar in the two groups, which each contained 109 patients. The RFA group had a shorter

2018 EvidenceUpdates

167. Sofosbuvir/velpatasvir for hepatitis C virus infection

Sofosbuvir/velpatasvir for hepatitis C virus infection Sofosbuvir/velpatasvir for hepatitis C virus infection - NPS MedicineWise Log In Menu Featured topics Professional development Publications An independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Timely, independent, evidence-based information on new drugs and medical tests, and changes to the PBS and MBS. Featured topics Talk to a professional Information for consumers on prescription, over-the-counter (...) February 2019 4 February 2019 18 October 2018 Featured topic 20 years of helping Australians make better decisions about medicines, medical tests and other health technologies Partner with us Latest projects Search Search Search Search POPULAR Log in Log in All fields are required Email address* Password* Log in Breadcrumb And Text Resize Sofosbuvir/velpatasvir for hepatitis C virus infection Sofosbuvir/velpatasvir for hepatitis C virus infection 4 min read 25 October 2017 A single tablet regimen

2018 National Prescribing Service Limited (Australia)

168. Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4

Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4 Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4 - NPS MedicineWise Log In Menu Featured topics Professional development Publications An independent peer-reviewed journal providing critical commentary on drugs and therapeutics. Timely, independent, evidence-based information on new drugs and medical tests, and changes to the PBS and MBS (...) combination for chronic hepatitis C genotypes 1 and 4 Grazoprevir with elbasvir (Zepatier): fixed-dose combination for chronic hepatitis C genotypes 1 and 4 13 min read 21 April 2017 The first interferon-free, oral antiviral treatment option for chronic genotype 4 HCV infection Key points The first interferon-free treatment option for patients with chronic genotype 4 hepatitis C virus (HCV) infection Grazoprevir with elbasvir (Zepatier) fixed-dose combination is an all-oral antiviral regimen that can

2018 National Prescribing Service Limited (Australia)

169. Screening for hepatitis B

Screening for hepatitis B 1 Translation of the key statement of the final report S16-03 Screening auf Hepatitis B (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-03 Screening for hepatitis B 1 Extract of final report S16-03 Version 1.0 (...) Screening for hepatitis B 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis B Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-03 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

172. Hepatitis E Virus Infection

Hepatitis E Virus Infection EASL Clinical Practice Guidelines on hepatitis E virus infection q European Association for the Study of the Liver ? Summary Infection with hepatitis E virus (HEV) is a signi?cant cause of morbidity and mortality, representing an important global health problem. Our understanding of HEV has changed completely over the past decade. Previously, HEV was thought to be limited to certain developing countries. We now know that HEV is endemic in most high-income countries (...) and is largely a zoonotic infection. Given the paradigm shift in our understanding of zoonotic HEV and that locally acquired HEV is now the commonest cause of acute viral hepatitis in many European countries, the focus of these Clinical Practice Guidelines will be on HEV genotype 3 (and 4). 2018EuropeanAssociationfortheStudyoftheLiver.Publishedby Elsevier B.V. All rights reserved. Introduction Asacause ofsigni?cantmorbidity and mortality,infectionwith hepatitis E virus (HEV) represents an important global

2018 European Association for the Study of the Liver

173. Treatment of Hepatitis C

Treatment of Hepatitis C EASL Recommendations on Treatment of Hepatitis C 2018 q European Association for the Study of the Liver ? Summary Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the dis- ease, and because of developments in diagnostic (...) procedures and improvements in therapy and prevention. These European Association for the Study of the Liver Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards. 2018 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Introduction Hepatitis C virus (HCV) infection is one of the main causes of chronic liver disease worldwide. 1 The long-term natural history of HCV

2018 European Association for the Study of the Liver

174. Serum Vitamin D Levels in Treatment-naïve Chronic Hepatitis B Patients Full Text available with Trip Pro

Serum Vitamin D Levels in Treatment-naïve Chronic Hepatitis B Patients According to the demographic health survey conducted in 2015, Egypt had 10% documented prevalence of anti-HBc positive patients aged 1-59 and 1% viremic patients amongst the population in the same age group, with a domination of genotype D. Several studies claimed the possible role of vitamin D deficiency in hepatitis B virus (HBV) replication and disease progression.Serum vitamin D levels [25(OH D3] were assessed in 96 (...) HBeAg negative non-cirrhotic chronic HBV patients and 25 healthy subjects classified as following: Group I: 48 chronic HBV patients with persistently normal ALT levels and HBV DNA level < 2000 IU/mL for ≥ 6 months; Group II: 48 chronic HBV patients with CHB with persistently elevated ALT and HBV DNA level ≥ 2000 IU/mL for ≥ 6 months; and Group III: 25 apparently healthy subjects with normal liver enzymes and negative hepatitis viral markers were taken as the control group.Vitamin D was much more

2017 Journal of translational internal medicine

175. Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012. Full Text available with Trip Pro

Low Prevalence of Hepatitis B Vaccination Among Patients Receiving Medical Care for HIV Infection in the United States, 2009 to 2012. Persons with HIV infection are at increased risk for hepatitis B virus infection. In 2016, the World Health Organization resolved to eliminate hepatitis B as a public health threat by 2030.To estimate the prevalence of hepatitis B vaccination among U.S. patients receiving medical care for HIV infection ("HIV patients").Nationally representative cross-sectional (...) survey.United States.18 089 adults receiving HIV medical care who participated in the Medical Monitoring Project during 2009 to 2012.Primary outcomes were prevalence of 1) no documentation of hepatitis B vaccination or laboratory evidence of immunity or infection (candidates to initiate vaccination), and 2) initiation of vaccination among candidates, defined as documentation of at least 1 vaccine dose in a 1-year surveillance period during which patients received ongoing HIV medical care.At the beginning

2017 Annals of Internal Medicine

176. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review Full Text available with Trip Pro

Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review Hepatocellular carcinoma (HCC) is a leading cause of liver-related death worldwide. Hepatitis C virus (HCV) infection is a major cause of advanced hepatic fibrosis and cirrhosis, with significantly increased risk for development of HCC. The morbidity and mortality of HCV-related HCC remains high, as rates of HCV cirrhosis continue to increase. The long-term goal of antiviral therapy for chronic HCV is to reduce complications

2017 Journal of clinical and translational hepatology

177. Alcoholic Hepatitis: Lost in Translation Full Text available with Trip Pro

Alcoholic Hepatitis: Lost in Translation Alcoholic hepatitis is the most severe and acute form of alcoholic liver disease. The mortality rate associated with alcoholic hepatitis is high, largely due to the lack of suitable pharmacological interventions. While there has been substantial research in the area, generating pharmacological interventions has been plagued by the lack of a robust mouse model both for testing and for understanding the underlying pathology. A number of major notable (...) advances have been made in this area recently, with the goal of generating a mouse model of alcoholic hepatitis. The purpose of this article is to review recent advances in modeling alcoholic liver disease both in vitro and in vivo in the mouse, and place them in the context of the greater spectrum of alcoholic liver disease, with a focus on how we can translate current advances into a high-fidelity model of alcoholic hepatitis. In addition, we will review the basic mechanisms of alcoholic hepatitis

2017 Journal of clinical and translational hepatology

178. Correction to: Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection Full Text available with Trip Pro

Correction to: Lack of relationship between PTEN 32-bp and TP53 16-bp Ins/Del polymorphisms and chronic hepatitis B virus infection [This corrects the article DOI: 10.1007/s13337-017-0391-7.].

2017 Virusdisease

179. Autoimmune Hepatitis in the Asia-Pacific Area Full Text available with Trip Pro

Autoimmune Hepatitis in the Asia-Pacific Area Autoimmune hepatitis has been considered as a relatively rare immunological liver disease, especially in the Asia-Pacific area. Although the diagnosis criteria and immunosuppressive treatment regimens have been established, there are still some challenges. According to the different presentations, the personalized management of patients who suffer from this disease, including those with chronic or acute severe onset, the autoantibody-negative (...) phenotype and cirrhosis are necessarily descriptive. Each subgroup of patients should receive an individualized therapy. Here, we review the recent studies of autoimmune hepatitis, mainly focusing on the epidemiology and genetics, personalized diagnostics, individualized treatment strategies, special subgroups and outcomes. Most of the research in the literature is based on Japanese and Chinese populations.

2017 Journal of clinical and translational hepatology

180. Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy Full Text available with Trip Pro

Prediction of histologic alcoholic hepatitis based on clinical presentation limits the need for liver biopsy The clinical presentation of alcoholic hepatitis (AH) can be mimicked by other alcoholic liver diseases. The aim of this study was to identify clinical features that predict AH on liver biopsy. Biopsies from patients hospitalized for presumed severe AH were used to identify a derivation cohort (101 patients) and validation cohort (71 patients). Using histologic scores for hepatocyte

2017 Hepatology communications